Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: A systematic review and meta-analysis

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Zang, Jiajie ^a   Wu, Shunquan ^a   Tang, Lei ^a   Xu, Xudong ^b   Bai, Jie ^b   Ding, Caicui ^c   Chang, Yue ^b   Yue, Long ^b   Kang, Enming ^b   He, Jia ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; GEFITINIB; PLACEBO; VANDETANIB; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PROGRESSION FREE SURVIVAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; THYROID CANCER; TREATMENT DURATION; CLINICAL TRIAL (TOPIC); ELECTROCARDIOGRAPHY; INCIDENCE; MIDDLE AGED; NEOPLASM; PATHOPHYSIOLOGY; RISK; RISK FACTOR;

CLINICAL TRIALS AS TOPIC; ELECTROCARDIOGRAPHY; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASMS; ODDS RATIO; PIPERIDINES; QUINAZOLINES; RISK FACTORS;

EID: 84857158314     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030353     Document Type: Review

References (38)

1. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, et al. (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62: 7284-7290.
2. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, et al. (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645-4655.
3. Wells SA, Gosnell JE, Gagel RF, Moley J, Pfister D, et al. (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28: 767-772.
4. Wells SA, et al. Vandetanib in locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind Phase III Trial (ZETA): Poster (1007PD) presented to ESMO conference in October 2010.
5. Anon, FDA approves new treatment for rare form of thyroid cancer. www.fda.gov April 6,2011.http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm250168.htm (accessed April 17, 2011).
6. Herbst RS, Sun Y, Eberhardt WE, Germonpre P, Saijo N, et al. (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11: 619-626.
7. Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, et al. (2009) Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 27: 2523-2529.
8. Leboulleux S, Bastholt L, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary or follicular;DTC): a randomized, double-blind phase II trial;Poster (1008 PD) presented to ESMO conference in October 2010.
9. Yang TS, Oh DY, Guimbaud R, et al. (2009) Vandetanib plus mFOLFOX6 in patients with advanced colorectal cancer (CRC): A randomized, double-blind, placebo-controlled phase II study. J Clin Oncol 27: 15s (suppl; abstr 4084).
10. Horti J, Widmark A, Stenzl A, Federico MH, Abratt RP, et al. (2009) A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm 24: 175-180.
11. Hsu C, Yang TS, Huo TL, et al. Evaluation of vandetanib in patients with inoperable hepatocellular carcinoma (HCC): a randomized, double-blind, parallel group, multicentre, phase II study.Joint ECCO 15-34TH ESMO Multidisciplinary Congress 2009,Abstract No: PD-6518. Accessed November 2, 2009.
12. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, et al. (2005) Cardiotoxicity of cancer therapy. J Clin Oncol 23: 7685-7696.
13. Viskin S, Justo D, Halkin A, Zeltser D, (2003) Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 45: 415-427.
14. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, et al. (2011) Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 29: 1059-1066.
15. Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, et al. (2008) A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 3: 386-393.
16. National Cancer Institute CTC v 2.0 and Common Terminology Criteria for Adverse Events Criteria V3.0 (CTCAE). http://ctep.cancer.gov/reporting/ctc.html (accessed April 2, 2011).
17. Fazio S, Palmieri EA, Lombardi G, Biondi B, (2004) Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 59: 31-50.
18. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
19. Woodward M, eds. (2005) Epidemiology: design and data analysis, 2nd edn Boca Raton Chapman and Hall/CRC Press.
20. Higgins JPT, Green S, eds. (2011) Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. The Cochrane Collaboration,http://www.cochrane-handbook.org.
21. Begg CB, Mazumdar M, (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics Dec;50 (4): 1088-1101.
22. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
23. Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, et al. (2007) Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 25: 4278-4284.
24. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, et al. (2008) Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26: 5407-5415.
25. Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, et al. (2005) A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 11: 3369-3376.
26. Barbey JT, Pezzullo JC, Soignet SL, (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21: 3609-3615.
27. Varterasian M, Meyer M, Fingert H, Radlowski D, Asbury P, et al. (2003) Baseline heart rate-corrected QT and eligibility for clinical trials in oncology. J Clin Oncol 21: 3378-3379.
28. Brell JM, (2010) Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy. Prog Cardiovasc Dis 53: 164-172.
29. Strevel EL, Ing DJ, Siu LL, (2007) Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25: 3362-3371.
30. Gillen MS, Miller B, Chaikin P, Morganroth J, (2001) Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br J Clin Pharmacol pp. 201-204.
31. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, et al. (2003) Risk stratification in the long-QT syndrome. N Engl J Med 348: 1866-1874.
32. Ojamaa K, Sabet A, Kenessey A, Shenoy R, Klein I, (1999) Regulation of rat cardiac Kv1.5 gene expression by thyroid hormone is rapid and chamber specific. Endocrinology 140: 3170-3176.
33. Bakiner O, Ertorer ME, Haydardedeoglu FE, Bozkirli E, Tutuncu NB, et al. (2008) Subclinical hypothyroidism is characterized by increased QT interval dispersion among women. Med Princ Pract 17: 390-394.
34. Colzani RM, Emdin M, Conforti F, Passino C, Scarlattini M, et al. (2001) Hyperthyroidism is associated with lengthening of ventricular repolarization. Clin Endocrinol (Oxf) 55: 27-32.
35. van Noord C, van der Deure WM, Sturkenboom MC, Straus SM, Hofman A, et al. (2008) High free thyroxine levels are associated with QTc prolongation in males. J Endocrinol 198: 253-260.
36. Crowley WF, Ridgway EC, Bough EW, Francis GS, Daniels GH, et al. (1977) Noninvasive evaluation of cardiac function in hypothyroidism. Response to gradual thyroxine replacement. N Engl J Med 296: 1-6.
37. Danzi S, Klein I, (2004) Thyroid hormone and the cardiovascular system. Minerva Endocrinol 29: 139-150.
38. de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, et al. (2011) Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 29: 1067-1074.